{{Infobox drug
| drug_name = 
| IUPAC_name = (6''S'')-2-[(3-chloro-4-fluorophenyl)methyl]-8-ethyl-9-hydroxy-''N'',6-dimethyl-1,10-dioxo-6,7-dihydropyrazino[3,4]pyrrolo[3,4-b]pyridazine-4-carboxamide
| image = MK-2048.svg
| alt = 
| caption = MK-2048

<!--Clinical data-->
| tradename = 
| Drugs.com = 
| MedlinePlus = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = 正在接受调查（2016）
| routes_of_administration = 

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number = 
| ATCvet = 
| ATC_prefix = 无
| ATC_suffix = 
| PubChem = 11554427
| DrugBank = 
| ChEMBL = 1237018
| ChemSpiderID = 25058456

<!--Chemical data-->
| C=21 | H=21 | Cl=1 | F=1 | N=5 | O=4
| molecular_weight  = 461.87 g/mol
| StdInChI = 1S/C21H21ClFN5O4/c1-4-26-8-10(2)28-16-14(18(29)17(28)21(26)32)20(31)27(25-15(16)19(30)24-3)9-11-5-6-13(23)12(22)7-11/h5-7,10,32H,4,8-9H2,1-3H3,(H,24,30)/t10-/m0/s1
| StdInChIKey = IOYLKNABOQYKKY-JTQLQIEISA-N
| smiles = CCN1CC(N2C3=C(C(=O)C2=C1O)C(=O)N(N=C3C(=O)NC)CC4=CC(=C(C=C4)F)Cl)C
}}

{{ctm}}

'''MK-2048'''系第二代[[整合酶抑制剂|整合酶抑制剂]]，是抗病毒药品，用于对抗[[HIV|HIV]]感染。其较前代整合酶抑制剂药物[[拉替拉韦|拉替拉韦]]<ref group="注">英文：raltegravir，又称MK-0518。商品名为“Isentress”。</ref>的优点是，该药物对HIV整合酶的有效抑制时间长达4倍。MK-2048作为暴露前阻断药物（PrEP）的实用性正在研究当中。<ref>Keith Alcorn. [http://www.aidsmap.com/en/news/B30D4C80-B2C3-4912-84E7-3EF4F414360A.asp Ralvetgravir shows potential for use as PrEP drug] {{Wayback|url=http://www.aidsmap.com/en/news/B30D4C80-B2C3-4912-84E7-3EF4F414360A.asp |date=20100103034130 }} AIDSmap.com. 28 April 2009. Accessed 8 Nov 2009.</ref>

MK-2048由[[默克藥廠|默克藥廠]]开发。<ref>Mark Mascolini. [http://www.natap.org/2009/PK/PK_10.htm Merck Offers Unique Perspective on Second-Generation Integrase Inhibitor.] {{Wayback|url=http://www.natap.org/2009/PK/PK_10.htm |date=20170604023850 }}  10th International Workshop on Clinical Pharmacology of HIV Therapy, April 15–17, 2009, Amsterdam.  Accessed 8 Nov 2009.</ref>

==注释==
{{Reflist|group="注"}}

==参考==
{{Reflist}}

[[Category:整合酶抑制剂|Category:整合酶抑制剂]]
[[Category:试验药物|Category:试验药物]]